Abstract: A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGB?, INF? and interleukin?. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT.

Abstract: The present invention relates to a compound comprising a carrier molecule, said carrier molecule being linked to a further molecule, said further molecule being at least one cyclic peptide, said cyclic peptide comprising in the cyclic peptide portion thereof at least one sequence encoding a cell receptor recognising peptide (RRP) and with the proviso that the compound is not a naturally occuring receptor agonist or antagonist. Preferably, the RRP is of a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is upregulated on HSC during disease. In particular, the RRP may be of a receptor selected from the group of PDGF receptor, collagen type VI receptor, cytokine receptor(s) such as TGF?, IFN? and interleukin 1?. Preferably, the cyclic portion of the cyclic peptide comprises at least the amino acid sequence RGD or KPT.

Abstract: The invention relates to pharmaceutical compositions suitable for treating or curing clinical complications mediated by endotoxin, including sepsis. The compositions contain components suitable for detoxifying endotoxin rendering it less deleterious to mammals such as humans, in particular to patients with reduced host-defence resistance. The invention also relates to pharmaceutical compositions suitable for stimulating bone formation, e.g. for mending broken bone or for prophylaxis or therapy of metabolic bone diseases such as osteoporosis and osteomalacia and pharmaceutical compositions for decreasing or inhibiting undesired bone formation. The pharmaceutical compositions according to the invention are directed at modulating phosphatase activity in vivo.

Abstract: The invention relates to pharmaceutical preparations which are suitable for treating viral infections, including influenza and immunodeficiency diseases and which can also be used in vitro, to inhibit fusion of virus-infected cells with non-infected cells, which preparations contain modified proteins or polypeptides as active substance or substance contributing to the action or as carrier for other substances, which are also active, which modified proteins or polypeptides have acquired an additional net negative charge by derivatisation of their amino groups and/or other basic functional groups with aconitic acid which prevents protonation of basic amino acids and/or other basic functional groups or replaces basic amino acids and/or other basic functional groups by one or more functional groups having a negative charge, and to modified proteins and polypeptides themselves and their preparation and use.